Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
ESGO 2021
📢And that’s a wrap on #ASCO23! We can go back home full of memories and an online journal full of content for you to catch up on! Visit http://vjoncology.com for our in-person coverage of #ASCO23 today!
@VJOncology @ASCO #ASCO23 #Cancer #OncTwitter #MedTwitter
🎥Today at #ASCO23, we spoke with @PTarantinoMD of @DanaFarber on the results of a population-based study assessing the prognosis and trends in chemo use for patients with stage IA TNBC.
➡️Full interview coming soon to http://VJOncology.com!
@ASCO #BreastCancer #BCSM #TNBC
🎥@RobinL_Jones of @royalmarsdenNHS discusses the INTRIGUE trial findings on ripretinib in patients with GIST at #ASCO2023. Although no PFS or OS improvements overall, patients pretreated with imatinib show OS improvement :
➡️⬅️
@ASCO #UroOnc #UroSoMe
Updated overall survival findings from the Phase III INTRIGUE trial
Robin Jones, MBBS, MRCP, MD, The Royal Marsden Hospital, London, UK, discusses overall survival findings from the Ph...
ow.ly
🎥It was great speaking with Nikolaos Trikalinos, MD, of @WUSTLmed at #ASCO23 on the emerging treatment landscape for patients with advanced extrapulmonary neuroendocrine carcinoma!
Check out http://VJOncology.com for interviews with leading experts from the meeting!
@ASCO
🎥We had the pleasure of speaking to @JSabari of @nyulangone on KRAS-mutated non-small cell #lungcancer earlier this morning at #ASCO23 in Chicago!
đź“·Watch this space for the interview! http://VJOncology.com
@ASCO
#NSCLC #SCLC #LCSM https://twitter.com/i/web/status/1665753740085714944
ESGO 2021
📢And that’s a wrap on #ASCO23! We can go back home full of memories and an online journal full of content for you to catch up on! Visit http://vjoncology.com for our in-person coverage of #ASCO23 today!
@VJOncology @ASCO #ASCO23 #Cancer #OncTwitter #MedTwitter
🎥Today at #ASCO23, we spoke with @PTarantinoMD of @DanaFarber on the results of a population-based study assessing the prognosis and trends in chemo use for patients with stage IA TNBC.
➡️Full interview coming soon to http://VJOncology.com!
@ASCO #BreastCancer #BCSM #TNBC
🎥@RobinL_Jones of @royalmarsdenNHS discusses the INTRIGUE trial findings on ripretinib in patients with GIST at #ASCO2023. Although no PFS or OS improvements overall, patients pretreated with imatinib show OS improvement :
➡️⬅️
@ASCO #UroOnc #UroSoMe
Updated overall survival findings from the Phase III INTRIGUE trial
Robin Jones, MBBS, MRCP, MD, The Royal Marsden Hospital, London, UK, discusses overall survival findings from the Ph...
ow.ly
🎥It was great speaking with Nikolaos Trikalinos, MD, of @WUSTLmed at #ASCO23 on the emerging treatment landscape for patients with advanced extrapulmonary neuroendocrine carcinoma!
Check out http://VJOncology.com for interviews with leading experts from the meeting!
@ASCO
🎥We had the pleasure of speaking to @JSabari of @nyulangone on KRAS-mutated non-small cell #lungcancer earlier this morning at #ASCO23 in Chicago!
đź“·Watch this space for the interview! http://VJOncology.com
@ASCO
#NSCLC #SCLC #LCSM https://twitter.com/i/web/status/1665753740085714944
Sign-up for our Newsletter!
Keep up to date with all the latest news with our monthly newsletter
